What we are about
At Cortexa Therapeutics, we are committed to advancing innovative treatments for ALS through rigorous scientific research. Our approach targets a novel mechanism in ALS pathology—abnormal calcium influx—using precision therapies that have never before been tested in clinical trials. By developing targeted treatments aimed at reducing excitotoxicity and restoring motor neuron function, we believe we can change the trajectory of ALS.
Our Path to Human Trials
Bringing a new treatment from concept to human trials is a structured and highly regulated process. Each phase requires careful execution, substantial funding, and a commitment to transparency. Our research process includes:
Preclinical Validation – Testing our compounds in laboratory models to demonstrate safety, efficacy, and mechanism of action.
Regulatory Approval for Clinical Testing – Preparing an Investigational New Drug (IND) application for FDA approval to proceed to human trials.
Phase 1 Clinical Trials – Conducting initial human studies to assess safety and dosage.
Phase 2 and 3 Trials – Expanding trials to determine therapeutic efficacy and refine treatment protocols before seeking FDA approval.
Each of these steps requires funding, collaboration, and the support of the scientific and patient communities. While our goal is to secure NIH and ALS Foundation research grants, these grants typically require preliminary data and feasibility studies. This is where early funding is critical.
How Your Support Fuels Progress
Every donation we receive directly supports the advancement of our research. Funding helps us:
Conduct laboratory studies to refine our approach.
Produce high-quality data necessary for NIH and ALS Foundation grants.
Engage with regulatory agencies to ensure a smooth path to human trials.
Build collaborations with top-tier research institutions to accelerate development.
We understand the importance of transparency, and we are committed to keeping donors informed about the progress of our research. Through regular updates, published findings, and open communication, we ensure that every contribution is making a meaningful impact.
Together, we have the opportunity to drive real change in ALS treatment. By supporting Cortexa Therapeutics, you are directly contributing to the next generation of ALS research and helping bring novel therapies closer to patients.